Overview |
bs-5231R |
Bid (Ser61) Polyclonal Antibody |
WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human |
Mouse |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic phosphopeptide derived from mouse Bid around the phosphorylation site of Ser61 |
Ser61 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
12122 |
Cytoplasm, Cell membrane |
Bid phospho S61; p-Bid phospho S61; BH3 interacting domain death agonist; p22 BID; BID; BH3-interacting domain death agonist; AltName: BH3-interacting domain death agonist p15; BH3-interacting domain death agonist p13; p13 BID; BH3-interacting domain death agonist p11; p11 BID. |
Bid, a BH3 domain containing proapoptotic Bcl2 family member, is localized in the cytosolic fraction of cells as an inactive precursor. Its active form is generated upon proteolytic cleavage by caspase 8 in the Fas signaling pathway. Cleaved Bid translocates to mitochondria and releases its potent proapoptotic activity, which in turn induces cytochrome c release and mitochondrial damage. The cytochrome c releasing activity of Bid was antagonized by Bcl2. Mutation in the SH3 domain can diminish the cytochrome c releasing activity. In animal model studies, Bid deficient mice are found resistant to the lethal effects of death factor signals relayed through Fas. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |